A COVID-19 vaccine developed at the University of Oxford will be tried on humans in the UK from Thursday this week.
Health Secretary Matt Hancock today said he was throwing everything at the attempt to develop the first vaccine in the world.
The Government will give the scientists an extra £20million to help with their project, Mr Hancock said.
The vaccine, known as ChAdOx1 nCoV-19 will be tried in conjunction with the University Hospital Southampton.
It is the first British-made vaccine to go into clinical trials and carries with it huge hopes that it will provide a key to getting out of lockdown and banishing COVID-19 from society.
The virus has now infected more than 125,000 people and killed 17,339 in the UK and the UK is on course to end up one of the worst-hit nations in the world.
It is hoped that this vaccine will be a permanent cure for the treatment of Covid-19 when it is administered on people on Thursday.
Content created and supplied by: Abdullateef12 (via Opera
News )
Opera News is a free to use platform and the views and opinions expressed herein are solely those of the author and do not represent, reflect or express the views of Opera News. Any/all written content and images displayed are provided by the blogger/author, appear herein as submitted by the blogger/author and are unedited by Opera News. Opera News does not consent to nor does it condone the posting of any content that violates the rights (including the copyrights) of any third party, nor content that may malign, inter alia, any religion, ethnic group, organization, gender, company, or individual. Opera News furthermore does not condone the use of our platform for the purposes encouraging/endorsing hate speech, violation of human rights and/or utterances of a defamatory nature. If the content contained herein violates any of your rights, including those of copyright, and/or violates any the above mentioned factors, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com and/or report the article using the available reporting functionality built into our Platform
See More
COMMENTS